Myelodysplastic syndromes

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O'Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. ThompsonPeter Westervelt, Benton Wheeler, Dorothy A. Shead, Maoko Naganuma

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

Original languageEnglish (US)
Pages (from-to)838-874
Number of pages37
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Gore, S. D., Head, D., Komrokji, R., Maness, L. J., Millenson, M., O'Donnell, M. R., Shami, P. J., Stein, B. L., Stone, R. M., ... Naganuma, M. (2013). Myelodysplastic syndromes. JNCCN Journal of the National Comprehensive Cancer Network, 11(7), 838-874. https://doi.org/10.6004/jnccn.2013.0104